Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia
Viruses · 2025
DOI: 10.3390/v17060743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Amgalan Byambasuren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Benzimidazoles, Sofosbuvir. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Liver Disease Free Arkhangai project.
Abstract (Originalsprache)
(1)
Background
Hepatitis C virus (HCV) infection poses a significant health burden, particularly in Mongolia, where the HCV prevalence is notably high. This study evaluates the long-term outcomes of HCV treatment with ledipasvir/sofosbuvir, focusing on mortality, viral relapse, and hepatocellular carcinoma (HCC) development. (2)
Methods
This prospective, longitudinal cohort study initially enrolled patients with chronic HCV in Mongolia between 2016 and 2017, focusing on those who completed the five-year follow-up (n = 303). The study measured long-term mortality, HCC development, and viral relapse, employing non-invasive methods to assess liver fibrosis and liver function. (3)
Results
At the outset, 98.2% of the patients achieved undetectable HCV RNA levels. Over five years, 6.27% experienced viral relapse and 3.30% developed hepatocellular carcinoma (HCC), with a mortality rate of 5.94%. In a multivariable analysis, the significant predictors for HCC occurrence included age (OR = 1.081, 95% CI = 1.021–1.145), liver cirrhosis (OR = 5.866, 95% CI = 1.672–22.577), and GGT level (OR = 1.011, 95% CI = 1.004–1.018). The independent predictors of mortality included age (OR = 1.083, 95% CI = 1.024–1.147), liver cirrhosis (OR = 6.529, 95% CI = 1.913–22.281), and GGT (OR = 1.011, 95% CI = 1.004–1.017). (4)
Conclusions
This study demonstrates that ledipasvir/sofosbuvir effectively suppresses HCV initially and maintains low viral relapse rates over the long term. However, it emphasizes the need for continued management to reduce the long-term risk of HCC and mortality, especially in patients with severe liver fibrosis or cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
- General Hospital of the Arkhangai Province, Tsetserleg 65191, Mongolia.
- Health Department of the Arkhangai Province, Tsetserleg 65089, Mongolia.
- Department of Physiology, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
- Department of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
- Mongolian Academy of Medical Sciences, Ulaanbaatar 14210, Mongolia.
ORCID-Profile: Oidov Baatarkhuu
Förderung
- The Liver Disease Free Arkhangai project
Zitieren
APA
Byambasuren, A., Gyarvuulkhasuren, B., Erdenebat, B., Nyamdavaa, K., & Baatarkhuu, O. (2025). Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia. Viruses. https://doi.org/10.3390/v17060743
Vancouver
Byambasuren A, Gyarvuulkhasuren B, Erdenebat B, Nyamdavaa K, Baatarkhuu O. Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia. Viruses. 2025. doi:10.3390/v17060743
BibTeX
@article{Byambasuren2025,
author = {Byambasuren, Amgalan and Gyarvuulkhasuren, Buyankhishig and Erdenebat, Byambatsogt and Nyamdavaa, Khurelbaatar and Baatarkhuu, Oidov},
title = {Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17060743}
}
EUVIMED